Live Breaking News & Updates on Japan Business Unit

Stay updated with breaking news from Japan business unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Daiichi Sankyo : List of Materiality (997KB) -October 31, 2023 at 05:32 am EDT

List of Materiality

Materiality on Business

Creating Innovative
. ....

Sustainable Procurement , Japan Research Institute , Nomination Committee , Product Information Center , Daiichi Sankyo Chemical Pharma Co , Healthcare Inc , Compensation Committee , Ds Group , Our Mission , Daiichi Sankyo Group , Stable Supply , Highest Quality , Japan Business Unit , Information Center , Net Promoter Score , Business Foundations , Fulfilling Our Mission , Diverse Range , People Who Create Our , Supervisory Board , Notable Industry Code Violations , Governance Code , Drafted Human Rights Due Diligence , Directors Regulations , Sustainable Procurement Survey , Value Report ,

Daiichi Sankyo : Announces Appointments of Directors and Audit & Supervisory Board Members(265.9KB

Press Release

Daiichi Sankyo Announces Appointments of Directors and Audit & Supervisory Board Members

Tokyo, Japan - - Daiichi Sankyo. | May 16, 2023 ....

Noritaka Uji , Kazuaki Kama , Shoji Hirashima , Takaaki Nishii , Masako Watanabe , Yukiko Imazu , Mitsuhiro Matsumoto , Ryoichi Watanabe , Kenji Sato , Hiroyuki Okuzawa , Yasuhiro Komatsu , Sunao Manabe , Miyuki Arai , Sawako Nohara , Alimentos Ltda , Masahiko Ohtsuki , National Police Agency , Quality Safety Science At Gunma University , Quality Safety Management Division Of The Company , Gunma University Hospital , Supervisory Board Members Of The Company , Ipse Marketing Inc , Sankyo Company , Office Of Audit Supervisory Board Members , Quality Assurance Regulatory Affairs , Itabashi Chuo Medical Center ,

Daiichi Sankyo unveils Blood cancer drug EZHARMIA in Japan

Adult T-cell leukemia-lymphoma (abbreviated ATLL or ATL) is a rare and aggressive hematologic malignancy that is caused by human T-cell lymphotropic virus type 1 (HTLV-1). ....

United States , Yoshinori Kaneshima , Daiichi Sankyo , Japan Ministry Of Health , Head Of Marketing Division , Corporate Officer , Marketing Division , Japan Business Unit , North America , Daiichi Sankyo News , Valemetostat Tosilate , Adultt Cell Leukemia Lymphoma , Blood Cancer , Blood Cancer Drug ,

Kite Pharma, Daiichi Sankyo revise YESCARTA CAR T-Cell Therapy licensing agreement

Tokyo: Kite Pharma, Inc., a Gilead Company, (hereafter Kite), and Daiichi Sankyo Co., Ltd. have jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo . ....

United States , El Segundo , Christi Shaw , Shoji Hirashima , Daiichi Sankyo , Kite Pharma Inc , Daiichi Sankyo Co Ltd , Gilead Company , Gilead Sciences , Gilead Sciences Inc , Kite Pharma , Marketing Authorization , Kite Cell , Therapy Business Unit , Senior Executive Officer , Japan Business Unit , Axicabtagene Ciloleucel ,

Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan

Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan ....

United States , Santa Monica , Foster City , El Segundo , Shoji Hirashima , Jacquie Ross , Tracy Rossin , Daiichi Sankyo , Kieko Ishikawa , Christi Shaw , Kite Pharma Inc , Japan To Gilead Sciences , Gilead Sciences , Gilead Sciences Inc , Sustainable Development Of Society , Exchange Commission , Daiichi Sankyo Co Ltd , Gilead Company , Japan Ministry Of Health , Innovative Global Healthcare Company , Transfer Yescarta Marketing Authorization , Kite Cell Therapy Business Unit , Promotion Activities , Japan After , Marketing Authorization Transfer , Marketing Authorization ,